As a first step to being a successful organization, we take pride in retaining key scientific talent of high caliber with diverse skill set to serve the needs of our internal research as well as our service based clients. Our core management team consists of experts with extensive experience in the early as well as late stage drug discovery process. Along with core expertise in medicinal chemistry, process chemistry that includes cGMP scale up of cytotoxic as well as non cytotoxic chemical entities, pharmacokinetics and biology, we have a Ph.D. scientist with over 10 years of experience in major biopharmaceutical industries that can provide services in molecular modeling, computer aided drug design (CADD), and cheminformatics (CIX) in various target classes such a kinases, proteases, nuclear receptors and GPCR’s. In addition, we have Ph.D. scientists that have extensive experience in Molecular Biology techniques, Bioinformatics, cloning and recombinant protein synthesis. The rich experience in molecular and disease biology combined with computational data mining, data analysis and data visualization to support drug discovery allows for a more complete package for in-house as well as client based needs.

Francis X. Tavares, Ph.D.
Founder
Dr. Tavares has over 10 years of drug discovery experience in the pharmaceutical industry. After receiving his Ph.D. degree in 1996 under the direction of Dr. Albert I. Meyers at Colorado State University, he completed his postdoctoral studies in 1998 at the University of Texas at Austin with Dr. Philip D. Magnus.  Dr. Tavares joined GlaxoSmithKline as a Research Investigator in the department of medicinal chemistry in 1998, where he progressed through the ranks to become a Group Manager.  Dr. Tavares has gained extensive knowledge and experience in the field of osteoporosis and metabolic diseases.  Dr. Tavares has proposed and championed over 15 metabolic targets encompassing areas of metabolic, inflammation, immunology, cancer, and cardiovascular diseases.  Dr. Tavares has lead multidisciplinary teams in early as well as late stage drug discovery processes consisting of representatives from Chemistry, Biology, Cheminformatics and ADME. He has had experience in working on multiple target classes such as Proteases, Kinases, and GPCR’s. He has been a co-inventor on eight patents and has over 30 research articles published in peer-reviewed journals.